Oragenics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on July 25, 2017. The report details the completion of a previously announced Series A Convertible Preferred Stock financing transaction with three accredited investors.
Key Financial Metrics
- Total Financing Amount: $3.0 million in Series A Convertible Preferred Stock.
- Proceeds Received (Second Closing): $1.698 million received on July 25, 2017.
- Proceeds Received (First Closing): Approximately $1.302 million received on May 10, 2017.
- Conversion Terms: The full $3.0 million is convertible into 12 million shares of Common Stock at a fixed price of $0.25 per share.
- Warrants Issued:
- First Closing: 4,621,037 warrants.
- Second Closing: 6,024,124 warrants.
- Total Warrants: 10,645,161 shares.
- Warrant Exercise Price: $0.31 per share.
- Warrant Term: 7 years (non-exercisable for 6 months post-issuance).
Note: This filing does not provide data on revenue, profit, cash flow, operating margins, debt levels, or liquidity ratios.
Material Changes
The primary material change is the receipt of the remaining $1.698 million in capital, contingent upon shareholder approval required by NYSE MKT listing rules. This completes the $3.0 million financing agreement entered into on May 10, 2017.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard securities law disclosures. The securities were sold in reliance on exemptions from registration under Section 4(2) and Regulation D (Rule 506) of the Securities Act of 1933. The Preferred Stock, Warrants, and underlying Common Stock are unregistered and may not be offered or sold in the United States absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the shareholder approval status required by NYSE MKT listing rules that triggered the second closing.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for covenants, redemption rights, and liquidation preferences associated with the Series A Preferred Stock.
- Confirm the dilution impact of the 12 million convertible shares and 10.6 million warrant shares on existing shareholders.
- Check the company's current cash position to understand how the $3.0 million proceeds will be utilized.